The average Acadia Pharmaceuticals stock price prediction forecasts a potential upside of 18.64% from the current ACAD share price of $26.34. What is ACAD's forecast return on assets (ROA) for 2023-2026?Find the latest ACADIA Pharmaceuticals Inc. (ACAD) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.View the latest ACADIA Pharmaceuticals Inc. (ACAD) stock price, news, historical charts, analyst ratings and financial information from WSJ.NASDAQ:ACAD .. I have been along with this one for a few months now. Around this price range is where we see big-time moves. This $21.88 level is a key level for this stock. It has been in a downtrend since it hit its 3 month high at the end of December. With how the market has been to begin this y NASDAQ:ACAD .. I have been along with this one ...Find the latest ACADIA Pharmaceuticals Inc. (ACAD) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Sep 7, 2023 · marketbeat.com - July 28 at 9:47 AM. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Expected to Earn Q1 2025 Earnings of ($0.15) Per Share. marketbeat.com - July 28 at 8:30 AM. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Recommendation of "Moderate Buy" by Brokerages. Jul 21, 2023 · Everyone at Acadia shares in our commitment to make a difference for our mothers and fathers. For our daughters and sons. For our grandparents, friends and neighbors. For the millions of people impacted by neurological disorders and fighting for their future every day. We are Acadia – fiercely committed to our mission of elevating life ... Jul 14, 2023 · Share. Shares of Acadia Pharmaceuticals ( NASDAQ:ACAD) have gained about 23% in yesterday’s extended trading session. The upside can be attributed to the expansion of the company’s agreement with Australia’s Neuren Pharmaceuticals ( AU:NEU) for Rett syndrome treatment trofinetide, marketed by ACAD under the name Daybue in the U.S. Dec 22, 2021 · Acadia Pharmaceuticals ( ACAD 0.69%), a mid-cap biotech company that focuses on neuroscience therapies, saw its shares rise 10.6% on Wednesday. The stock has been volatile, with a 52-week low of ... ACAD short interest surges, indicating growing pessimism among investors. Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. ACADIA Pharmaceuticals Inc. shares valued at $289,970 were sold by Schneyer Mark C. on Aug 21. At $29.00 per share, Schneyer Mark C. sold 10,000 shares.The average trading volume for ACAD on September 13, 2023 was 1.58M shares. ACAD) stock’s latest price update. The stock price of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) has plunged by -3.65 when compared to previous closing price of 27.13, but the company has seen a -5.19% decline in its stock price over the last five trading sessions.Jul 14, 2023 · Share. Shares of Acadia Pharmaceuticals ( NASDAQ:ACAD) have gained about 23% in yesterday’s extended trading session. The upside can be attributed to the expansion of the company’s agreement with Australia’s Neuren Pharmaceuticals ( AU:NEU) for Rett syndrome treatment trofinetide, marketed by ACAD under the name Daybue in the U.S. The average twelve-month price prediction for ACADIA Pharmaceuticals is $31.81 with a high price target of $95.00 and a low price target of $12.00. Learn more on ACAD's analyst rating history.The ACADIA Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.Acadia Pharmaceuticals Inc. (ACAD) Message Board - Company Name: Acadia Pharmaceuticals Inc., Stock Symbol: ACAD, Industry: Biotechs - Total Posts: 3186 - Last Post: 07/17/2023 10:34:44 PM - company/specific stock boardACAD Stock Message Board for Investors. Acadia Pharmaceuticals Inc. Stock Price, News and Company Updates. Message Board Total Posts: 114Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.Real time Acadia Pharmaceuticals (ACAD) stock price quote, stock graph, news & analysis.Everyone at Acadia shares in our commitment to make a difference for our mothers and fathers. For our daughters and sons. For our grandparents, friends and neighbors. For the millions of people impacted by neurological disorders and fighting for their future every day. We are Acadia – fiercely committed to our mission of elevating life ...ACAD Stock 12 Months Forecast. Based on 13 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $31.15 with a high forecast of $42.00 and a low forecast of $20.00. The average price target represents a -0.35% change from the last price of $31.26.Find the latest news headlines from ACADIA Pharmaceuticals Inc. Common Stock (ACAD) at Nasdaq.com. A high-level overview of ACADIA Pharmaceuticals Inc. (ACAD) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.ACAD Earnings Date and Information. ACADIA Pharmaceuticals last issued its earnings data on August 2nd, 2023. The biopharmaceutical company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.13. The business earned $165.20 million during the quarter, compared to analyst estimates of $163.86 million.The ACADIA Pharmaceuticals Inc. stock price gained 0.418% on the last trading day (Friday, 8th Sep 2023), rising from $26.34 to $26.45. During the last trading day the stock fluctuated 1.71% from a day low at $26.23 to a day high of $26.68. The price has fallen in 6 of the last 10 days and is down by -6.87% for this period.Acadia Pharmaceuticals ( ACAD 0.69%), a mid-cap biotech company that focuses on neuroscience therapies, saw its shares rise 10.6% on Wednesday. The stock has been volatile, with a 52-week low of ...The average twelve-month price prediction for ACADIA Pharmaceuticals is $31.81 with a high price target of $95.00 and a low price target of $12.00. Learn more on ACAD's analyst rating history.radios peru
Sep 13, 2023 · Their ACAD share price forecasts range from $12.00 to $95.00. On average, they predict the company's stock price to reach $31.81 in the next year. This suggests a possible upside of 20.3% from the stock's current price. View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts. ACAD’s stock style is Small Value. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are ...The ACADIA Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention. ACAD's dividend yield, history, payout ratio, proprietary DARS™ rating & much more! Dividend.com: The #1 Source For Dividend Investing. marketbeat.com - July 28 at 9:47 AM. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Expected to Earn Q1 2025 Earnings of ($0.15) Per Share. marketbeat.com - July 28 at 8:30 AM. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Recommendation of "Moderate Buy" by Brokerages.The average trading volume for ACAD on September 13, 2023 was 1.58M shares. ACAD) stock’s latest price update. The stock price of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) has plunged by -3.65 when compared to previous closing price of 27.13, but the company has seen a -5.19% decline in its stock price over the last five trading sessions.Acadia Pharmaceuticals (NASDAQ: ACAD) stock is taking a beating on Tuesday after revealing an update from the U.S. Food and Drug Administration (FDA). The FDA supplied a response to the company ...Acadia Pharmaceuticals Stock Chart and Share Price Forecast, Short-Term "ACAD" Stock Prediction for Next Days and Weeks Walletinvestor.com Acadia Pharmaceuticals Inc (ACAD) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024elf streaming
Investors were uneasy about the move. On today's stock market, ACAD stock tumbled 20.8% to close at near 21.45.. ACAD Stock Faces New Catalysts. Nuplazid is already approved to treat ..."Acadia (ACAD) was the best performing stock in 2019 in the portfolio, rising by more than 164%. The biggest jump happened at the end of the third quarter when the company announced the successful ...Sep 12, 2023 · ACAD Stock Overview. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. Jun 17, 2022 · Acadia Pharmaceuticals Inc. ACAD, -1.01% said Friday its stock will be halted from trading Friday as a U.S. Food and Drug Administration panel meets virtually to discuss a new drug application for ... Acadias rare-disease drug to cost $575,000 to $595,000. (MarketWatch) Mar-10-23 09:45PM. Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older. (Business Wire) Mar-07-23 09:45AM.Jul 14, 2023 · ACAD Stock Assessment. Per Seeking Alpha data, Acadia Pharmaceuticals has displayed notable stock momentum, outpacing the S&P 500 over the last year with a gain of 66.52%. Analysts forecast a ... Dec 7, 2021 · Over the past 3 months, 7 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are typically employed by large Wall Street banks and tasked with ... MSN MoneyThe weighted average target price per ACADIA Pharmaceuticals share in Oct 2025 is: 18.04. In Oct, the Positive dynamics for Momo shares will prevail with possible monthly volatility of 10.870% volatility is expected. Pessimistic target level: 17.21. Optimistic target level: 19.31.ACADIA Pharmaceuticals Inc. [ACAD] stock is trading at $28.01, up 2.34%. In order to assess the stock's recent performance, you can check whether its short-term value is rising or falling. The ACAD shares have gain 4.51% over the last week, with a monthly amount drifted -12.96%, and not seem to be holding up well overvalley high
ACADIA Pharmaceuticals Stock Forecast 09-13-2023. Forecast target price for 09-13-2023: $ 26.06. Positive dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 5.024%. Pessimistic target level: 25.23. Optimistic target level: 26.56.What happened. Shares of the mid-cap biopharma Acadia Pharmaceuticals ( ACAD -2.84%) fell by as much as 44% in pre-market trading Tuesday morning. The drugmaker's stock is crashing today in ...The ACADIA Pharmaceuticals Inc. stock price gained 0.418% on the last trading day (Friday, 8th Sep 2023), rising from $26.34 to $26.45. During the last trading day the stock fluctuated 1.71% from a day low at $26.23 to a day high of $26.68. The price has fallen in 6 of the last 10 days and is down by -6.87% for this period.So, when comparing one stock to another in a different industry, it's best make relative comparisons to that stock's respective industry values. -20.12% -235.99%Sep 8, 2023 · View ACADIA Pharmaceuticals Inc ACAD investment & stock information. Get the latest ACADIA Pharmaceuticals Inc ACAD detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Dec 7, 2021 · Over the past 3 months, 7 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are typically employed by large Wall Street banks and tasked with ... Investors were uneasy about the move. On today's stock market, ACAD stock tumbled 20.8% to close at near 21.45.. ACAD Stock Faces New Catalysts. Nuplazid is already approved to treat ...Stock Prices. Trefis. Looking at a longer time period, ACAD stock is up 38% from levels of $16 seen toward the end of 2018. The rise in the stock price over the last two years or so can be ...The trade volume for ACAD stock is 1.087M as of 9/12/2023. What is the current trade volume for ACADIA Pharmaceuticals Inc (ACAD) ? The current trading volume for ACAD stock is 1.087M .What this means: ACADIA Pharmaceuticals Inc. (ACAD) gets an Overall Rank of 59, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.Feb 28, 2023 · Acadia Pharmaceuticals Inc ACAD reported a Q4 EPS loss of $(0.26), missing the consensus of $(0.24) and sales of $136.49 million, beating the consensus of $134.07 million.; For FY23, the company ... Stock Prices. Trefis. Looking at a longer time period, ACAD stock is up 38% from levels of $16 seen toward the end of 2018. The rise in the stock price over the last two years or so can be ...Sep 12, 2023 · ACAD Stock Overview. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. the real real customer service
ACADIA Pharmaceuticals Inc (ACAD) stock is trading at $18.95 as of 10:23 AM on Monday, Mar 13, a decline of -$1.42, or -6.97% from the previous closing price of $20.37. The stock has traded between $18.73 and $20.15 so far today.ACADIA Pharmaceuticals Inc (ACAD) stock is trading at $18.95 as of 10:23 AM on Monday, Mar 13, a decline of -$1.42, or -6.97% from the previous closing price of $20.37. The stock has traded between $18.73 and $20.15 so far today.Share. Shares of Acadia Pharmaceuticals ( NASDAQ:ACAD) have gained about 23% in yesterday’s extended trading session. The upside can be attributed to the expansion of the company’s agreement with Australia’s Neuren Pharmaceuticals ( AU:NEU) for Rett syndrome treatment trofinetide, marketed by ACAD under the name Daybue in the U.S.But not all stocks are feeling the love. Rather, investors in Acadia Pharmaceuticals (NASDAQ: ACAD) are feeling pain following a more than 30% drop in ACAD stock. This afternoon’s move comes ...See ACADIA Pharmaceuticals Inc. (ACAD) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Acadia's rare-disease drug to cost $575,000 to $595,000. Acadia Pharmaceuticals Inc. ACAD said its newly approved treatment for Rett syndrome has an annual list price ranging from $575,000 to $595,000, according to a company spokesperson. The Food and Drug ... 6 months ago - Market Watch.ACAD Stock: Improvements On Several Scales Rett syndrome is a rare neurological condition that causes uncontrolled hand movements in, mainly, girls and women. It's caused by mutations on the X ...The stock price for ACADIA Pharmaceuticals Inc. (ACAD) currently stands at $28.34. The stock experienced a substantial increase in the last session, hitting $29.48 after starting at $29.48. The stock’s lowest price was $28.82 before closing at $29.02. ACADIA Pharmaceuticals Inc. experienced a13 analysts have issued 12 month price objectives for ACADIA Pharmaceuticals' stock. Their ACAD share price forecasts range from $12.00 to $95.00. On average, they predict the company's stock price to reach $31.81 in the next year. This suggests a possible upside of 20.3% from the stock's current price.The average Acadia Pharmaceuticals stock price prediction forecasts a potential upside of 18.64% from the current ACAD share price of $26.34. What is ACAD's forecast return on assets (ROA) for 2023-2026?Mar 9, 2021 · What happened. Shares of the mid-cap biopharma Acadia Pharmaceuticals ( ACAD -2.84%) fell by as much as 44% in pre-market trading Tuesday morning. The drugmaker's stock is crashing today in ... Sep 7, 2023 · marketbeat.com - July 28 at 9:47 AM. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Expected to Earn Q1 2025 Earnings of ($0.15) Per Share. marketbeat.com - July 28 at 8:30 AM. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Recommendation of "Moderate Buy" by Brokerages. Total equity. US$699.14 million (2019) Number of employees. 570 (June 30, 2020) Website. acadia .com. Footnotes / references. [1] Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California.Jul 28, 2023 · The stock price for ACADIA Pharmaceuticals Inc. (ACAD) currently stands at $28.34. The stock experienced a substantial increase in the last session, hitting $29.48 after starting at $29.48. The stock’s lowest price was $28.82 before closing at $29.02. ACADIA Pharmaceuticals Inc. experienced a ACADIA Pharmaceuticals Inc.’s current trading price is -8.03% away from its 52-week high, while its distance from the 52-week low is 127.68%. The stock’s price range for this period has been between $13.73 and $33.99 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 2.39 million for the ...wonder appSep 13, 2023 · Their ACAD share price forecasts range from $12.00 to $95.00. On average, they predict the company's stock price to reach $31.81 in the next year. This suggests a possible upside of 20.3% from the stock's current price. View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts. Sep 14, 2023 · See the latest ACADIA Pharmaceuticals Inc stock price (NASDAQ:ACAD), related news, valuation, dividends and more to help you make your investing decisions. Find the latest ACADIA Pharmaceuticals Inc. (ACAD) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. ACAD Stock 12 Months Forecast. Based on 13 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $31.15 with a high forecast of $42.00 and a low forecast of $20.00. The average price target represents a -0.35% change from the last price of $31.26.Join Stocktwits for free stock discussions, prices, and market sentiment with millions of investors and traders. Stocktwits is the largest social network for finance.Acadia Pharmaceuticals ( ACAD 0.69%), a mid-cap biotech company that focuses on neuroscience therapies, saw its shares rise 10.6% on Wednesday. The stock has been volatile, with a 52-week low of ...A high-level overview of ACADIA Pharmaceuticals Inc. (ACAD) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.ACAD Stock Overview ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases.Total equity. US$699.14 million (2019) Number of employees. 570 (June 30, 2020) Website. acadia .com. Footnotes / references. [1] Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California.What this means: ACADIA Pharmaceuticals Inc. (ACAD) gets an Overall Rank of 59, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value.ACADIA Pharmaceuticals Inc. Message board - Online Community of active, educated investors researching and discussing ACADIA Pharmaceuticals Inc. Stocks.ACADIA Pharmaceuticals Inc. Common Stock (ACAD) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.ACADIA Pharmaceuticals Inc (ACAD) stock is trading at $18.95 as of 10:23 AM on Monday, Mar 13, a decline of -$1.42, or -6.97% from the previous closing price of $20.37. The stock has traded between $18.73 and $20.15 so far today.Jun 21, 2022 · What happened. Shares of Acadia Pharmaceuticals ( ACAD 1.49%) were crashing 35.4% as of 11 a.m. ET on Tuesday. The steep decline came after a Food and Drug Administration (FDA) advisory committee ... manatee county fair
Stock Prices. Trefis. Looking at a longer time period, ACAD stock is up 38% from levels of $16 seen toward the end of 2018. The rise in the stock price over the last two years or so can be ...MSN MoneyDownload Pipeline Chart. Our pipeline information may include a reference to an investigational agent or an investigational use of the FDA approved product. Safety and efficacy for investigational uses or agents have not been established or approved by the FDA. This table provides an overview of selected projects in development and can be ... ACADIA Pharmaceuticals Inc.’s current trading price is -8.03% away from its 52-week high, while its distance from the 52-week low is 127.68%. The stock’s price range for this period has been between $13.73 and $33.99 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 2.39 million for the ...ACADIA Pharmaceuticals Stock Forecast 09-13-2023. Forecast target price for 09-13-2023: $ 26.06. Positive dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 5.024%. Pessimistic target level: 25.23. Optimistic target level: 26.56.Sep 7, 2023 · ACADIA Pharmaceuticals Stock Forecast 09-13-2023. Forecast target price for 09-13-2023: $ 26.06. Positive dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 5.024%. Pessimistic target level: 25.23. Optimistic target level: 26.56. Aug 15, 2023 · ACADIA Pharmaceuticals Inc. [ACAD] stock is trading at $28.01, up 2.34%. In order to assess the stock's recent performance, you can check whether its short-term value is rising or falling. The ACAD shares have gain 4.51% over the last week, with a monthly amount drifted -12.96%, and not seem to be holding up well over ACADIA Pharmaceuticals Stock (NASDAQ: ACAD) stock price, news, charts, stock research, profile.ACAD Earnings Date and Information. ACADIA Pharmaceuticals last issued its earnings data on August 2nd, 2023. The biopharmaceutical company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.13. The business earned $165.20 million during the quarter, compared to analyst estimates of $163.86 million.At the current price of $27, ACAD stock is actually trading below the levels seen in March 2020, while the broader S&P500 Index has rallied 77% over the same period. However, the selling now ...Find the latest ACADIA Pharmaceuticals Inc. (ACAD) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. timer 1 minute 30 seconds
Aug 15, 2023 · ACADIA Pharmaceuticals Inc. [ACAD] stock is trading at $28.01, up 2.34%. In order to assess the stock's recent performance, you can check whether its short-term value is rising or falling. The ACAD shares have gain 4.51% over the last week, with a monthly amount drifted -12.96%, and not seem to be holding up well over Stock Price Forecast. The 15 analysts offering 12-month price forecasts for ACADIA Pharmaceuticals Inc have a median target of 33.00, with a high estimate of 42.00 and a low estimate of 13.00. The ...Jul 14, 2023 · Share. Shares of Acadia Pharmaceuticals ( NASDAQ:ACAD) have gained about 23% in yesterday’s extended trading session. The upside can be attributed to the expansion of the company’s agreement with Australia’s Neuren Pharmaceuticals ( AU:NEU) for Rett syndrome treatment trofinetide, marketed by ACAD under the name Daybue in the U.S. ACAD | Complete ACADIA Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. The stock of Acadia Pharmaceuticals (NASDAQ: ACAD), a biopharmaceutical company focused on neuroscience drugs, has seen a rise of 26% over the last month.ACAD stock rose from levels of around $19 ...At the time of writing, the total D/E ratio for ACAD stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00. ACAD Stock Stochastic Average. Today’s raw stochastic average for ACADIA Pharmaceuticals Inc. over the last 50 days is 53.60%.This indicates a decrease from the raw stochastic average of the past 20 days, which was ...